BioSpace.com

Biotech and Pharmaceutical
News & Jobs
Search the Site
 
   
Biotechnology and Pharmaceutical Channel Medical Device and Diagnostics Channel Clinical Research Channel BioSpace Collaborative    Job Seekers:  Register | Login          Employers:  Register | Login  

NEWSLETTERS
Free Newsletters
Archive
My Subscriptions

NEWS
News by Subject
News by Disease
News by Date
PLoS
Search News
Post Your News
JoVE

CAREER NETWORK
Job Seeker Login
Most Recent Jobs
Browse Biotech Jobs
Search Jobs
Post Resume
Career Fairs
Career Resources
For Employers

HOTBEDS
Regional News
US & Canada
  Biotech Bay
  Biotech Beach
  Genetown
  Pharm Country
  BioCapital
  BioMidwest
  Bio NC
  BioForest
  Southern Pharm
  BioCanada East
  US Device
Europe
Asia

DIVERSITY

INVESTOR
Market Summary
News
IPOs

PROFILES
Company Profiles

START UPS
Companies
Events

INTELLIGENCE
Research Store

INDUSTRY EVENTS
Biotech Events
Post an Event
RESOURCES
Real Estate
Business Opportunities

 News | News By Subject | News by Disease News By Date | Search News
eNewsletter Signup
Miles
Km80.5

   

Vaccinex, Inc. Announces Initiation of a Phase 1 Clinical Trial of VX15/2503 Antibody in Multiple Sclerosis Patients


1/7/2013 11:20:09 AM

ROCHESTER, N.Y., Jan. 7, 2013 /PRNewswire/ -- Vaccinex, Inc. announced today that it has initiated a Phase 1 clinical trial to assess the safety, tolerability and pharmacokinetics of therapeutic antibody candidate VX15/2503 in patients with multiple sclerosis.

VX15/2503 is a novel humanized monoclonal antibody targeting the multi-functional protein semaphorin 4D (SEMA4D), and represents the second clinical trial for this investigational drug. Signaling cascades initiated by SEMA4D regulate activation and migration of inflammatory cells, inhibit remyelination, and disrupt endothelial tight junctions leading to breakdown of the blood-brain barrier. Each of these mechanisms is known to contribute to the severity and progression of neuroinflammatory/neurodegenerative diseases including multiple sclerosis. Studies in multiple animal models have shown that anti-SEMA4D antibody can successfully ameliorate disease severity.

Dr. Maurice Zauderer, President and Chief Executive Officer of Vaccinex, said: "It is particularly gratifying for Vaccinex to translate into the clinic the first therapeutic to target this important new class of regulatory molecules. Research in our own and other laboratories has shown that the multiple activities of SEMA4D have a coordinated detrimental effect on progression of neurological diseases, several types of cancer, and some other inflammatory and/or degenerative conditions. Vaccinex is currently completing a parallel trial of VX15/2503 antibody in patients with solid tumors and plans to continue to advance studies of the therapeutic benefit of this unique and novel agent."

About Vaccinex, Inc.

Founded in 1997 and located in Rochester, NY, Vaccinex, Inc. is a privately held clinical-stage biotechnology company engaged in the discovery and development of human therapeutic monoclonal antibodies and vaccines to treat serious diseases with unmet needs, including cancer, multiple sclerosis, and other autoimmune diseases. www.vaccinex.com.

Press Contact
Raymond E. Watkins, Chief Operating Officer, Vaccinex, Inc.
+1.585.271.2700

SOURCE Vaccinex, Inc.



Read at BioSpace.com

   

ADD TO DEL.ICIO.US    ADD TO DIGG    ADD TO FURL    ADD TO STUMBLEUPON    ADD TO TECHNORATI FAVORITES